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1. Introduction
The first human liver transplant (LT) was performed in 1963 by Starzl and colleagues at the
University of Colorado in Denver [1]. Since then, LT has become a life-saving procedure for
patients with irreversible chronic and acute liver failure (ALF) [2-4].Only a few cases were per‐
formed during the following 15-year as the results were not satisfactory and 1-year survival
rate was only 30% due to early rejection and graft failure. In the late 1970s and early 1980s, the
implementation of cyclosporine-based immunosuppression led to the doubling of the 1-year
survival rate and LT, from an experimental procedure, became standard of care for patients
with end stage liver disease (ESLD) [5]. In the last two decades, significant advances occurred
in all aspects of LT, including donor management, recipient selection, surgical techniques, im‐
munosuppression, and postoperative care. These changes have resulted in considerable im‐
provements in the care provided to LT recipients, and the current overall 1-year survival is
now in excess of 85%, with 5- and 10-year survival ranging between 70-85% and 60-70%, re‐
spectively [6-9]. Despite all these major advances, biliary complications after LT still represent
a common and challenging problem for both patients and their caregivers.
The main aim of this chapter is to inform the reader on the current indications and contraindica‐
tions for LT, the risk factors associated with postoperative biliary complications and to evaluate
the endoscopic techniques currently available for the diagnosis and treatment of these patients.
2. Epidemiology of liver failure
Liver disease is a common and broad definition used to describe any acute and chronic liver
disorders that includes:
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• Steatosis
• Fibrosis
• Cirrhosis
• Acute and chronic hepatitis (viral, metabolic, autoimmune etc.)
• Primary hepatic malignancies (hepatocellular carcinoma and cholangiocarcinoma)
ESLD encompasses all those clinical conditions characterized by the irreversible deterioration
of the hepatic function and is responsible for over two million outpatient visits and over 750,000
hospitalizations per year only in the United States (US) [10]. Currently, chronic liver disease
and cirrhosis are among the tenth leading causes of death, and the annual number of fatalities
has remained essentially unchanged (25,000 per year) over the past two decades (Table
1).Every year in the US, over 40,000 patients develop ESLD and approximately 2,000 ALF [11].
Unfortunately, only 5,000–6,000 will undergo LT [12] and the current mismatch between the
number of available grafts and the number of patients waiting for LT is responsible for 5 to
10% yearly mortality rate.
Primary Disease % of Mortality
Heart disease 31.0
Malignant neoplasms 23.2
Cerebrovascular disease 6.8
COPD 4.8
Trauma 4.2
Pneumonia and influenza 3.9
Diabetes 2.8
Suicide 1.3
Kidney diseases 1.1
Chronic liver disease or cirrhosis 1.1
Data from Murphy S. Deaths: final data for 1998. National vital statistics reports. Hyattsville, MD: National Center for
Health Statistics, 2000, Vol. 48.
Table 1. The ten leading causes of deaths in United States.
3. Indications for liver transplantation
LT is indicated for all the clinical conditions summarized in Table 2. Because LT is the only
cure for ESLD, patients who develop signs of liver decompensation should be referred to
transplant centers before their conditions deteriorate to a point when LT is no longer feasible
(Table 3).
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Acute Liver Failure
Viral Hepatitis A,B,C,D
Acetaminophen overdose and other drugs
Autoimmune hepatitis
Cryptogenic liver disease
Wilson’s disease
Budd-Chiari syndrome
Fatty infiltration—acute fatty liver of pregnancy
Reye’s syndrome
Cirrhosis from Chronic Liver Disease
Chronic hepatitis B and C virus infection
Alcoholic liver disease
Autoimmune hepatitis
Cryptogenic liver disease
Nonalcoholic fatty liver disease
Metabolic Liver Disease
Wilson’s disease
Hereditary hemochromatosis
Alpha-1 antitrypsin deficiency
Glycogen storage disease
Cystic fibrosis
Glycogen storage disease I and IV
Crigler-Najjar syndrome
Galactosemia
Type 1 hyperoxaluria
Familial homozygous hypercholesterolemia
Hemophilia A and B
Vascular Diseases
Budd-Chiari syndrome
Veno-occlusive disease
Cholestatic Liver Diseases
Primary biliary cirrhosis
Primary sclerosing cholangitis
Secondary biliary cirrhosis
Biliary atresia
Alagille syndrome
Byler’s disease
Miscellaneous
Adult polycystic liver disease
Nodular regenerative hyperplasia
Caroli’s disease
Severe graft-versus-host disease
Amyloidosis
Sarcoidosis
Hepatic trauma
Table 2. Main causes of irreversible liver failure.
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Ascites
Coagulopathy
Encephalopathy
Jaundice
Cachexia
Hepatorenal Syndrome
Hepatopulmonary Syndrome
Pulmonary Hypertension
Persistent and intractable pruritus
Table 3. Some of the most common clinical manifestations of liver failure.
Cirrhosis is the main indication in the adult population and it accounts for more than 80% of
LTs performed in the world. Other frequent indications in the US are: hepatitis C (21%),
alcoholic liver disease (16%), cholestatic liver disease including primary biliary cirrhosis and
sclerosing cholangitis (17%). Less frequent indications include: chronic hepatitis (hepatitis B,
autoimmune hepatitis), metabolic disease (e.g. Wilson’s disease, nonalcoholic steatohepatitis),
fulminant hepatic failure, and non-metastatic HCC [13].
In the pediatric population the most frequent indication for LT includes biliary atresia and
congenital metabolic diseases.
3.1. Acute liver failure
ALF accounts for 5% of all LT in the US. The most common causes are: toxins or drug induced
liver injury (e.g., acetaminophen), viral hepatitis, or, less commonly, autoimmune hepatitis or
Wilson disease [14-16]. In approximately 15-17% there are no identifiable causes [17].
3.2. Hepatocellular carcinoma
Most transplant centers would perform LT for patients with unresectable HCCs who satisfy
the Milan criteria (absence of metastatic disease and one of the following two conditions: a
single lesion with maximum diameter equal or smaller than 5cm in diameter or three or fewer
lesions, the largest of which measures up to 3cm in diameter) [18]. The 5-year survival rate in
this setting is 75-80%, which is comparable to survival rates of patients undergoing LT for
benign conditions. At the University of California, San Francisco (UCSF), LT has been advo‐
cated for patients without extra-hepatic disease and affected by single tumors measuring up
to 6.5 cm or by 3 or fewer lesions with the largest being equal or smaller than 4.5 cm and with
a total tumor burden of 8 cm or less with similar short and long term outcomes to patients
within the Milan criteria [19-22].
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3.3. Cholangiocarcinoma
In  the  past,  all  patients  with  cholangiocarcinoma (CC)  were  thought  to  be  poor  candi‐
dates for LT due to their  high rate of  recurrent disease and poor survival.  However,  at
the Mayo Clinic in Minnesota,  a novel therapeutic protocol for unresectable hilar CC or
CC arising in the setting of  PSC combines an intensive protocol  that  uses  neo-adjuvant
chemo and radiation therapy prior to LT. Patients treated at that centre have shown ex‐
cellent  1-year  survival  up  to  82% and comparable  to  patients  undergoing  LT  for  other
causes [16, 21]. On the other hand, patients with intrahepatic CC appear to be still  poor
candidates  due  to  their  poor  prognosis  even  if  treated  with  neo-adjuvant  chemo-radia‐
tion therapy [23].
4. Contraindications to liver transplantation
Contraindications to LT can be divided in two main groups: relative contraindications and
absolute contraindications. Relative contraindications are all those conditions that prevent
optimal  outcomes,  and therefore,  should be  corrected whenever  possible  prior  to  trans‐
plantation (Table 4) [1 11 24].  Absolute contraindications, instead, are not reversible and
lead to unsatisfactory outcomes and their presence should prevent LT if recognized in time
(Table 5) [3 5].
• HIV/AIDS
• Age "/> 65 years
• Severe malnutrition
• Other irreversible organ failure
• Previous major upper abdominal surgeries
• Poor functional status
• Previous history of poor compliance
Table 4. Relative contraindications to LT.
• Severe cardiopulmonary disease
• Irreversible cerebral injury
• Sepsis or active infection
• Most of the extra-hepatic malignancies except for non-melanoma skin cancer
• Major vascular thrombosis of the arterial or venous system preventing successful arterial or venous reconstructions
• Active alcohol or drug abuse
• Sever psychological conditions
Table 5. Absolute contraindications to LT.
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5. Pediatric liver transplantation
Pediatric LT is one of the most successful transplant procedures [25].  The 1-year patient
survival  rate  is  83% to  91%,  depending  on  the  age  of  the  child  at  the  time  of  surgery
[26].Five-year patient  survival  is  also excellent,  ranging from 82 to 84%. The number of
pediatric LTs per year has remained steady in the last  decade, averaging approximately
600 per year in the US. About 55% of these transplants are for end-stage chronic liver dis‐
ease, the majority of these due to biliary atresia; about 25% are for metabolic liver diseas‐
es,  10%  for  ALF,  and  5%  for  hepatic  malignancies  [27  28].  Underlying  diagnoses  of
children undergoing LT are presented in Table 6. In pediatric LT, there are very few abso‐
lute  contraindications.  These  include  conditions  in  which  LT  is  futile  and  will  not  im‐
prove  the  overall  survival  or  quality  of  life,  and  this  list  of  conditions  has  shortened
dramatically over the years (Table 7).
Diagnosis Frequency (%)
Cholestatic liver disease
Biliary atresia
Others: Alagille syndrome, sclerosing cholangitis, progressive familial intrahepatic
cholestasis
48
Fulminant hepatic failure 11
Metabolic liver disease
Primary hepatic disease:
Wilson disease, a-1-antitrypsin deficiency, tyrosinemia, cystic fibrosis
Primarily nonhepatic disease:
ornithine transcarbamylase deficiency, primary hyperoxaluria type 1, organic
academia
13
Liver tumors 4
Others 9
Data from Ng VL, Fecteau A, Shepherd R, et al. Outcomes of 5-year survivors of pediatric liver transplantation: report on
461 children from a North American multicenter registry. Pediatrics 2008;122(6):e1128–35.
Table 6. Underlying diagnoses of children undergoing liver transplantation.
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Absolute contraindications:
Extrahepatic malignancy (considered incurable by standard oncologic criteria)
Sepsis
- Uncontrolled systemic infection
- Acquired immunodeficiency syndrome (AIDS)
Extrahepatic disease (incurable)
- Irreversible massive brain injury
- Uncorrectable congenital anomalies affecting major organs
Relative contraindications:
Malignancy that is considered cured or curable by standard oncologic criteria
Sepsis
- Treatable infection
- Human immunodeficiency virus
Extrahepatic disease
- Progressive extrahepatic disease
- Substance abuse
Table 7. Contraindications to pediatric liver transplantation.
6. Cadaveric graft allocation
To optimize the distribution of cadaveric grafts to patients who are in most need, the United
Network for Organ Sharing (UNOS) in the US has proposed the use of the Model for End-stage
Liver Disease (MELD) and Pediatric End-stage Liver Disease (PELD), which are numerical
scales reflecting the degree of organ dysfunction [29]. These scores are predictive of each pa‐
tient’s risk of dying while waiting for a LT in 3 months period. The MELD score, used for pa‐
tients aged 12 years and older, is based on serum bilirubin levels, international normalized
ratio (INR), and creatinine. The PELD score, in addition to the serum levels of bilirubin, INR
and albumin includes also the presence of growth failure and patients’ age, which are all asso‐
ciated with the mortality risk in children with liver failure. Alone, these scores are not sufficient
for the final allocation of liver grafts as other important factors need to be carefully evaluated
such as: the compatibility between the donor’s and the recipients’ blood groups, the size of the
graft in relation to the body size of the recipient, and finally, the fact that in some circumstances
available grafts are prioritized for individuals who suffers from ALF.
7. Surgical technical aspects of liver transplantation
During LT, biliary reconstruction is the final step before the abdominal wall is closed and pa‐
tients leave the operating room (Figure 1 –A,B,C,D). Biliary anastomoses are performed after
all the vascular anastomoses have been successfully completed and satisfactory hemostasis is
reached.
Liver Transplantation and Endoscopic Management of Bile Duct Complications
http://dx.doi.org/10.5772/52630
317
Endoscopy of GI Tract318
Liver Transplantation and Endoscopic Management of Bile Duct Complications
http://dx.doi.org/10.5772/52630
319
Figure 1. Temporal representation of all the necessary anastomoses performed during an orthotopic full organ LT
with interposition of the donor’s vena cava. After the native liver is mobilized and removed from the recipients’ ab‐
dominal cavity, the liver graft is positioned in the same location (orthotopic liver transplantation) and anastomosed to
the recipient’s vascular and biliary structures. The first anastomosis performed is the supra-hepatic vena cava (Figure
1A), the second is the infrahepatic vena cava (Figure 1B), the third is the portal vein anastomosis (Figure 1C). After the
portal vein anastomosis is completed, the liver graft is reperfused. The last vascular anastomosis is represented by the
hepatic artery reconstruction (Figure 1D) followed by the biliary duct anastomosis (Figure 1E).
An end-to-end duct-to-duct anastomosis is the reconstruction of choice in patients with healthy
native bile ducts of suitable caliber [30] as it reconstitutes the physiological hepato-enteric bili‐
ary cycle (Figure 1E). This technique is simpler and faster than the creation of biliary-enteric
anastomoses (Figure 2A) and, when indicated, the biliary system can be investigated and treat‐
ed endoscopically by retrograde cholangiography (ERCP). A side-to-side variant of the duct-to-
duct anastomosis has also been used by some groups with similar good results (Figure 2B) [31,
32]. On the other hand, the surgical technique that used the gallbladder as a conduit between the
donor’s and the recipient’s bile ducts or intestine, has been abandoned because of the associat‐
ed bile stasis and stone formation causing frequent episodes of cholangitis, which lead to surgi‐
cal  revisions  and  overall  inferior  outcomes(Figure  2C)  [33,  34,  35].  Roux-en-Y
hepaticojejunostomy (Figure 2A) is utilized in cases of preexisting disease of the native biliary
tract observed when patients are affected by primary sclerosing cholangitis or biliary atresia in
the pediatric population. In addition, this technique is often used when there is disparity in size
between the donor’s and the recipient’s bile ducts, when the common bile duct is very small and
at risk of developing strictures at the anastomotic site and it is usually the preferred technique
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for the biliary reconstruction during retransplantations because of the inadequate length of the
native biliary system [36, 37]. In the early years of living-donor LT and split LT, Roux-en-Y hep‐
atico-jejunostomy was also the standard biliary reconstructive technique. With growing experi‐
ence of the surgical technique and meticulous attention in preserving the blood supply around
the native common bile duct [38, 39], duct-to-duct anastomosis has become the preferred recon‐
struction technique even during right lobe living-donor transplantation in the adult popula‐
tion [40, 41],  as well during the right lobe split transplant [42, 43].  Initially, duct-to-duct
anastomosis created during the right lobe living-donor transplants was only performed when a
single donor duct was available. More recently, the use of the recipient right and left hepatic
ducts, as well as the cystic duct has been reported by several authors even when facing the need
of creating multiple biliary anastomoses [44, 45]. Alternatively, both duct-to-duct and bilioen‐
teric reconstructions may also be used simultaneously in the same patient.
Left biliary-jejunostomy remains the method of choice for biliary reconstruction when using
left lateral segment grafts during split livers or living related transplantations [46, 47] although,
even in these circumstances, a duct-to-duct anastomosis has been recommended by some
authors [48, 49].
8. Biliary complications after liver transplantation
Biliary complications after LTare relatively frequent and occur in 5-25% of patients and repre‐
sent one of the major causes of morbidity and even mortality in this group of patients [50, 51, 52,
53, 54, 55].The complication rate of the biliary system varies according to the surgical techni‐
ques and nature of the graft. Biliary complications are less frequent in patients undergoing LT
with the use of full size grafts (5-15%) while the incidence of biliary complications in living do‐
nor, split or reduced size grafts is much more significant and ranges between 15 to 30% [56, 57].
Biliary leaks and strictures occurring at the anastomotic site are the most common biliary
complications. Other less frequent adverse events are: sphincter of Oddi dysfunction, hemo‐
bilia, biliary obstruction from cystic duct mucoceles, stones, sludge or formation of biliary duct
casts that will be discussed later on in this chapter [50, 51, 58].
9. Temporal presentation of biliary complications
After LT, complications of the biliary tract can occur both in the immediate perioperative
period, as well as several months or years after the procedure.
Conventionally, biliary complications are divided into three main categories:
• Early Complications (observed within 30 days after LT)
• Delayed Complications (observed during the second and third month after LT)
• Late Complications (observed after 3 months post LT)
Liver Transplantation and Endoscopic Management of Bile Duct Complications
http://dx.doi.org/10.5772/52630
321
Endoscopy of GI Tract322
Figure 2. Graphical representation of the most common biliary reconstructions performed in liver transplantation. The
most common technique is the reconstruction with an end-to-end bile duct anastomosis as represented in Figure 1E.
With this technique, the two end of the donor’s and the recipient’s common bile ducts are anastomosed together
allowing the bile to flow in a very physiologic way. Less frequently, the bile duct reconstruction is obtained by creating
a Roux-en-Y bilioenteric anastomosis (Figure 2A) where the common bile duct of the donor is anastomosed to the
antimesenteric wall of a loop of small intestine of the recipient, or by creating a side-to-side bile duct anastomosis
(Figure 2B). In the past, a cholecysto-enteric anastomosis was often used to drain the bile but this technique has been
almost completely abandoned (Figure 2C).
10. Risk factors of biliary complications
Several factors have been identified as predisposing conditions for the development of biliary
complications in LT recipients. Among them the most common are: hepatic artery thrombo‐
sis, thermal and ischemic injury to the peri-biliary duct tissues, inferior quality of the liver
graft, prolonged cold and warm ischemia time, blood type incompatibility between the donor
and the recipient, infections and tension between the two ends of the biliary anastomosis.
10.1. Hepatic artery thrombosis or stenosis
The hepatic artery plays an important role in the blood supply of the bile duct and insufficient
arterial blood flow is responsible for both acute and chronic ischemia of the biliary system.
Acute ischemia can lead to anastomotic disruptions and subsequent biliary leaks in the
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immediate postoperative period or delayed strictures that can occur at the level of the
anastomosis or in other parts of the intra and extra-hepatic ducts.
10.2. Technical factors
During surgery the most common technical factors that can result in biliary complications
are: the excessive dissection of the periductal tissue during the procurement or during the
mobilization of the native liver,and the excessive use of electrocautery to control bleeding
from the peribiliary tissues. Another important risk factor for biliary anastomotic failures is
the presence of tension between the two ends of the biliary anastomosis that can lead to an
incomplete seal and subsequently to leaks and formation of peri-hepatic absesses.
10.3. Quality of the grafts and cold and warm ischemia times
Biliary complications are more frequent in recipients of grafts procured from donors after
cardiac death who have an increased risk of experiencing insufficient organ perfusion or
suboptimal oxigenation of the liver. This undesired warm ischemia time has been consid‐
ered one of the most important risk factors for biliary complications that frequently affect
recipients of livers from donors after cardiac death. In addition, biliary complications have
been encountered more frequently after the use of grafts from older donors, grafts with stea‐
tosis, and in all those circumstances where the grafts experience suboptimal cold storage
and prolonged cold or warm ischemia [59].
10.4. Placement of T-tubes
In the past, T-tubes were placed routinely in all patients undergoing LT to monitor the pro‐
duction of bile as a proxy for early graft function and, theoretically, to prevent anastomotic
strictures. The role of T-tubes in LT, in the era of endoscopic therapy, is much less apparent
and they have been almost unanimously abandoned. Comparative studies between post-LT
patients with and without T-tubes indicate that routine T-tube placement is associated with
a higher incidence of biliary complications including bile leaks and cholangitis [60, 61]. A
recent meta-analysis including more than 1,000 patients indicated that those patients with‐
out a T-tube had better outcomes compared with those with a T-tube, including fewer epi‐
sodes of cholangitis and fewer episodes of peritonitis [62].
10.5. Biliary reconstruction
The most common technique used for the reconstruction of the biliary system in patients
undergoing cadaveric LT is the duct-to-duct choledocho-choledochostomy anastomosis
(Figure 3A). When this technique is not feasible, most patients undergo a Roux-en-Y choledo‐
chojejunostomy (Figure 3B). Duct-to-duct choledochocholedochostomy has the advantage of
being easier and quicker to perform, it is more physiological and prevents enteric reflux into
the bile ducts, and it has also the advantage of allowing easier access to the biliay system by
endoscopic means [63]. Several studies have shown that the risk of biliary complications with
the Roux-en-Y reconstruction is similar, or only slightly higher compared with the duct-to-
duct anastomosis [51, 64].
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Figure 3. Graphical representation of the two most common biliary reconstruction after cadaveric liver treansplanta‐
tion. Figure 3A represent the classical duct-to-duct reconstruction where the donor’s bile duct is anastomosed to the
recipient bile duct. This anastomosis has the advantage of being less time-consuming than the biliary-enteric anasto‐
mosis (Figure 3B) and it allows a physiological flow of bile into the duodenum. Another significant advantage is that
the biliary system of patients undergoing a duct-to-duct anastomosis can be reached by endoscopic means. This al‐
lows the insertion of stents or dilatation when biliary leaks or stricture develop.
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10.6. Other risk factors
Several other predisposing factors for biliary complications have been identified. Among them,
the most frequent are: pre-LT cytomegalovirus infection [65, 66], LT performed between
donors and recipients with ABO blood group incompatibility, the diagnosis of primary
sclerosing cholangitis as the primary indication for LT and intra-abdominal infections in the
perioperative period.
11. Clinical presentation and diagnosis of biliary complications
The clinical presentations of biliary complications after LT can be challenging as they de‐
pend on the time of occurrence, degree of severity and patients’ characteristics. Elevation
of  the  recipient’s  white  blood  count,  fever,  abdominal  pain,  ileus  and  cholestasis  are
common  findings  in  patients  who  develop  early  biliary  complications.  Often,  immuno‐
suppressed patients can be asymptomatic for a relatively long period of time before they
manifest  any  clinical  condition  that  can  lead  to  the  appropriate  diagnosis.  In  asympto‐
matic  patients,  suspicion  of  a  biliary  complication  should  occur  in  the  presence  of  any
unexplained  elevation  of  serum aminotransferases,  total  bilirubin,  alkaline  phosphatase,
and gamma-glutamyltransferase levels in the absence of acute rejection. Biliary leaks are
often diagnosed as fluid collections on abdominal imaging performed for unrelated rea‐
sons.
12. Non-invasive diagnostic modalities
Noninvasive radiologic investigations usually begin with a trans-abdominal ultrasound (US),
which is often used in combination with Doppler examination of the flow characteristics of
the hepatic artery, portal and hepatic veins. Triphasic contrast computed tomography (CT),
magnetic resonance cholangiopancreatography (MRCP) and nuclear medicine HIDA scan are
usually complementary investigations to the original abdominal US. Further diagnostic steps
in the evaluation of these patients depend upon the initial findings. Among them, the most
frequently performed are: ERCP and percutaneous transhepatic cholangiography (PTC).
13. Invasive diagnostic modalities
13.1. Endoscopic retrograde cholangiopancreatography
ERCP plays a primary role in the management of biliary complications after LT. Despite
the lack of large randomized trials, ERCP has become the procedure of choice for all LT
patients with their biliary tract accessible to endoscopic manipulation. Post-ERCP compli‐
cations  are  similar  to  the  general  population  and  include:  pancreatitis,  bleeding,  infec‐
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tions  and perforation.  Overall,  the  complication  rate  in  this  population  ranges  between
2% to 6% [67, 68, 69, 70, 71, 72] confirming that ERCP is relatively safe even in this sub‐
set of immunocompromised patients who often have persistent thrombocytopenia due to
hyperspenism and transient coagulative dysfunction.
13.2. Percutaneous transhepatic cholangiography
PTC  and  percutaneous  transhepatic  biliary  drainage  (PTBD)  are  necessary  when  ERCP
can  not  be  performed  or  when  it  has  failed.  The  most  frequent  indication  for  PTC  in
post LT patients is the presence of a Roux-en-Y biliary enteric anastomosis that prevents
the  access  to  the  biliary  duct  by  endoscopic  approach.  In  comparison to  ERCP,  PTC is
more hazardous in the presence of thrombocytopenia or coagulopathy and it can be tech‐
nically very challenging when the intra-hepatic biliary ducts are not dilated, for example
in the presence of a bile duct anastomotic leak. On the other hand, anastomotic strictures
are responsible for the dilatation of the biliary ducts,  making PTC easier and safer.  The
determination  of  whether  to  perform ERCP or  PTC depends  upon anatomic  considera‐
tions,  the diameter of  the donor biliary tree,  and the overall  morbidity related to issues
of sedation and coagulation status [73, 74].
14. Biliary stents
Endoscopic biliary stents were first introduced in 1979 [75] primarily for the palliation of
malignant strictures. Until then, surgery (such as choledochojejunostomy, choledochoduo‐
denostomy, and cholecysto-jejunostomy) had been the mainstay of treatment. Initially, in‐
terventional  radiologists  developed percutaneous techniques that  allowed the placement
of external biliary drainages. Subsequently, the introduction of new methods allowed the
internalization of biliary drains that immediately became more attractive as patients did
not  suffer  from significant  fluid losses,  malnutrition due to  decreased intestinal  absorp‐
tion of lipids and fat-soluble vitamins (e.g. vitamin K, A, D, E). Plastic stents (Figure 4A
and 4B) have a median duration of 3-4 months as they are subject to obstruction due to
deposition  of  debris  in  their  lumen  and  subsequent  risk  of  ascending  cholangitis.  The
limited long-term patency rate  of  plastic  stents  fuelled the  development  of  metal  stents
that  are  significantly  larger  in  diameter  and  have  lower  propensity  to  obstruct.  Nowa‐
days,  metal  stents are available in various designs.  The designs differ from one another
in  the  diameter  of  the  expanded  stent,  diameter  of  the  delivery  system,  length  of  the
stent, and wall thickness [76]. Metal stents were conventionally of two types (ie, balloon-
mouthed or  self-expanding);  however,  nowadays  self-expandable  metallic  stents  (SEMS)
(Figure  4C)  are  more  commonly  used,  with  balloon-mouthed  stents  having  become
somewhat archaic.
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Figure 4. Plastic biliary stent inserted in a patient with anastomotic biliary leak after cadaveric liver transplantation.
The patient developed leukocytosis associated with new onset of jaundice and abdominal pain. A CT scan revealed a
large sub-hepatic fluid collection that was percutaneosly drained. The fluid aspirated was consistent with bile. During
the following days, the 24 hours drain output was consistently above 400 ml. An ERCP confirmed the presence of a
bile duct anastomotic partial dehiscence. A 10 French, 9 cm in length temporary plastic stent (Figure 4A) was inserted
across the anastomosis. During the following days, the drainage output decreased and on post-ERCP day 7 the patient
had no bile draining from the percutaneous drainage tha was subsequently taken out. After 3 months, the plastic
stent was removed during a second ERCP (Figure 4B) and the endoscopic cholangiogram revealed a complete resolu‐
Endoscopy of GI Tract328
tion of the leak and no anastomotic stricture. Figure 4C represents a non-covered metallic biliary stent with diameter
of 10 mm and 6 cm length. These stents are usually used for malignant biliary obstructions but, when covered by a
non-adsorbable layer that prevent tissue ingrowth into the stent, can be removed and are becoming popular even for
the treatment of benign biliary strictures and for post liver transplant biliary leaks. The advantages of metallic stents, in
comparison to plastic stents, are: larger diameters that result in longer patency rates, self-expanding material that al‐
lows constant dilatation in the areas of biliary stenosis, more flexibility and therefore better adherence to the biliary
walls. This last characteristic is very important when dealing with biliary leaks as covered metallic stents are able to
prevent bile extravasation and facilitate non-operative management even in severe anastomotic bile disruptions.
Metal stents can also be differentiated on the basis of stent composition, with namely stainless
steel or nitinol being used. Nitinol is an example of a biocompatible, super-elastic, and shape
memory alloy consisting of 55% nickel and 45% titanium. The strong inter-metallic bonds
between nickel and titanium have a very low reaction rate; thus, preventing immunological
responses and a decreased rate of corrosion.
Initially, SEMS featured an uncovered design but a limited patency on the account of tissue
overgrowth, cancer ingrowth [77] and poor removability led to the development of covered
self-expanding metal stents (CSEMS). These stents have a metallic skeleton and are covered
by a biocompatible, synthetic covering, which is resistant to the effects of bile, gastric, and
pancreatic secretions [78]. The increased incidence of migration associated with CSEMS,
however, paved the way for the development of partially CSEMS in which the distal and
proximal ends of the stent are uncovered and therefore prevent the risk of stent migration.
15. Postoperative biliary complications
15.1. Leaks
Bile leaks after LT occur in 2–25% of patients [79] and most present within one to three months
after surgery. Anastomotic dehiscences are due to technical errors, tension or for ischemia of
the bile duct edges due to hepatic artery thrombosis or because of devascularization of the
tissue surrounding the biliary tree. In addition, bile leaks can also occur from the cystic duct
remnants, the T-tube site or tract, from the gallbladder fossa or (in the case of living donor LT)
from the cut surface of the liver (Table 8).
• Surgical anastomosis (duct to duct, hepaticojejunostomy)
• Cystic duct stump
• T-tube site
• Ischemic injuries of the extra-hepatic bile duct
• Gallbladder fossa
• Cut surface of the liver in LDLT
Table 8. Causes and locations of leaks following liver transplantation.
Early leaks (within 4 weeks from LT) are usually due to ischemia or technical issues [80]. Late
bile leaks tend to occur following T-tube removal [80], as patients on high dose of steroids and
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other immunosuppressive medications have reduced ability to heal the T-tube insertion site
and seal the tract around the drain. Post LT bile leaks should be suspected in patients who
develop clinical deterioration, signs of peritoneal inflammation or fluid collections on cross
sectional imaging tests. A bile leak should also be suspected in patients who develop persistent
abdominal pain after removal of T-tube. It is very important to be aware that a relatively high
proportion of patients with late bile leaks present with late biliary strictures than do those with
early leaks.
Many bile leaks can be resolved non-operatively with early percutaneous or endoscopic
interventions [50-52, 55].When there is a low suspicion of a biliary leak, a radionucleotide scan
has reasonable accuracy for the presence of bile extravasation [81]. ERCP, though, is the gold
standard diagnostic method and should be performed in all patients when there is a high
suspicion for biliary leaks. Treatment for biliary leaks consists of placement of either an
endoscopic stent and/or a percutaneous stent/drain. If there is an associated stricture, then both
the leak and the stricture need to be bridged by the stent. Stent placement can result in up to
88% resolution of biliary leaks. Resolution of the leak occurs typically within 5 weeks but the
patient’s symptoms will resolve within days of stent insertion [82]. The stent should be left in
place for approximately 2 to 3 months because of problems with delayed healing that may
arise as a result of immunosuppression [59]. In cases where a T-tube is in place, small anasto‐
motic leaks can be diagnosed with a T-tube cholangiogram and can be managed by leaving
the tube open without further interventions. Instead of the transpapillary stent, a nasobiliary
tube can be inserted. An advantage of the nasobiliary tubes is that they permit cholangio‐
graphic follow-up without the need for further endoscopies [83], however, they are often
poorly tolerated and also divert bile away from the intestine, thereby decreasing the bioavail‐
ability of certain drugs.
Anastomotic leaks after Roux-en-Y choledochojejunostomies are less common. A suspected
bile leak in such patients can be diagnosed with a hepatobiliaryimino-diacetic acid (HIDA)
scan if patients do not have a drainage catheter in place. Standard ERC is often not feasible
because of anatomic difficulties in reaching the biliary anastomosis. Management is usually
performed with percutaneous internal-external drainage. Bile leaks in patients with Roux-en-
Y anatomy more often require surgical management.
Bilomas occur because of bile duct rupture and extravasation of bile into the hepatic paren‐
chyma or the abdominal cavity. Most post-LT bilomas occur in the perihepatic area. Small
bilomas communicating with the biliary tree may resolve spontaneously. Large bilomas not
communicating with the bile ducts should be treated with percutaneous drainage and
antibiotics. Surgery is indicated only when the bile leak cannot be controlled effectively with
endoscopic stenting.
15.2. Bile duct strictures
15.2.1. Introduction
Biliary strictures and bile leaks account for the majority of biliary complications after LT. The
incidence of biliary strictures after cadaveric LT ranges between 5 to 15% while the incidence
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is much higher after living donor liver transplantation where biliary leaks occur in 28–32% of
patients [84]. Although strictures can develop at any time post LT, they tend to occur in the
first 5–8 months after surgery [84, 85]. Strictures that occur early after are mostly attributable
to technical problems, whereas late strictures are mainly attributable to vascular insufficiency
and problems with the healing of tissues and fibrosis [63, 86]. A bile leak is an independent
risk factor for the development of a stricture, and for that reason, a bile leak requires emer‐
gent endoscopic therapy [66]. Strictures are classified as anastomotic (AS) or nonanastomotic
(NAS), depending on the stricture site (Table 9). NAS are defined as strictures that occur more
than 0.5 cm proximal to the anastomosis and tend to be multiple and longer in length (Table
9). NAS can be further classified into macroangiopathic, microangiopathic, and immunogenic
be the causes determining the stenosis of the bile duct (Table 10) [84, 87].
AS tend to occur later than NAS. They are usually shorter and localized to the anastomotic
site (Table 9) with an incidence of 4–9% [80, 84].Ischemic NAS usually presents within 1
year of OLT while immunological NAS usually present later than 1 year post-transplanta‐
tion [88, 89]. In contrast to AS, NAS can result in graft loss [90]. AS are generally the result
of scar formation (fibrosis), local ischemia, technical issues, or a bile leak in the post-opera‐
tive period [89, 91].
Biliary strictures
Anastomotic Non-anastomotic
Single
Short
Anastomosis site
Multiple
Long
Intrahepatitc and proximal to anastomosis
Table 9. Classification of biliary strictures.
Macroangiopathic Microangiopathic Immunogenic
Hepatic artery thrombosis Prolonged cold and warm ischemia times
Donation after cardiac death
Prolonged use of vasopressors in the donor
Chronic rejection
ABO incompatibility
Primary sclerosing cholangitis
Autoimmune hepatitis
Table 10. Non-anastomotic stricture classification.
15.2.2. Anastomotic strictures
Up to 80% of biliary strictures are anastomotic, occurring either at the choledocho-chole‐
dochostomy or choledocho-jejunostomy sites [51,  55].  AS typically reflect technical prob‐
lems  and  primarily  are  due  to  small  bile  leaks  resulting  in  a  peri-anastomotic  fibro-
inflammatory  response,  or  ischemia  at  the  end  of  the  bile  duct  resulting  in  a  fibro-
proliferative  response.  By  definition,  they  are  single  and  short  in  length,  making  them
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suitable for endoscopic intervention. The characteristic cholangiographic appearance of AS
is that of a thin narrowing in the area of the biliary anastomosis. In some patients, a nar‐
rowing of the anastomosis may become evident within the first 1 to 2 months after LT be‐
cause  of  postoperative  edema  and  inflammation  [89].  This  type  of  narrowing  has  an
excellent response to endoscopic balloon dilation and plastic stent placement; in most pa‐
tients, it resolves within 3 months and the anastomosis remains patent without further in‐
tervention. Except for the subset of patients with this early narrowing, most patients with
AS require ongoing ERCP sessions (every 2 to 3 months) with balloon dilation and long-
term stenting (for 12 to 24 months) (Figure 5). In most cases, an approach using balloon
dilation  with  diameters  of  6  to  8  mm and placement  of  7.0-  to  11.5-Fr  plastic  stents  is
more effective than balloon dilation alone [92]. Stents should be exchanged at 3-month in‐
tervals to avoid stent occlusion and the precipitation of bacterial cholangitis. Most patients
require several endoscopic interventions (mean of 3 to 5) with long-term success rates in
the  range  of  70% to  100% [52,  85,  89,  92].  The  placement  of  a  progressively  increasing
number of as well as diameter stents with each subsequent ERC has been shown to be a
successful  method of  treating  AS [93].  In  an  illustrative  study,  patients  who developed
biliary strictures after LT and who initially were treated endoscopically with balloon dila‐
tion and plastic stents had a recurrence rate of 18% with a mean time to recurrence of 110
days [94].
There is some clinical experience in temporary placement of a covered self-expanding metal
stent to reduce the need for repeated stent exchanges, but data are limited [95]. The difficulty
with the uncovered metallic self-expandable stent is that there is an inevitable reactive
hyperplasia that can be accompanied by secondary stone formation above the stent and there
may be a challenge in removing the stent once it has been in place for 6 to 9 months [96]. Fully
covered stents, by contrast, almost always are able to be removed endoscopically, as they do
not embed into the surrounding tissue. The data on this type of stent are limited and one article
reported the stents caused strictures in the bile duct mainly secondary to the anchoring point
in the distal proximal end [97]. Additionally, they may occlude secondary branch ducts, and
this technical aspect might limit their use in patients with right-lobe live-donor transplants.
Because of the high rates of success, endoscopic management should be considered the first
choice before considering percutaneous interventions or surgical repair in patients with duct-
to-duct anastomosis. In patients with Roux-en-Y choledochojejunostomy, management with
balloon enteroscopy ERC or PTC and dilation followed by placement of a percutaneous
transhepatic catheter is often necessary. Surgical intervention (usually a repair or conversion
to a Roux-en-Y choledochojejunostomy) is required when the ERC or PTC fails to adequately
treat AS.
15.2.3. Non-anastomotic strictures
NAS result mainly from hepatic artery thrombosis, increased cold ischemia time, or ABO
blood-type incompatibility. Less commonly these strictures can be caused by recurrence of the
underlying disease such as primary sclerosing cholangitis. They account for 10.0%to 25.0% of
all stricture complications after LT, with an incidence in the range of 0.5% to 10.0% [51, 52, 53,
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54, 55]. True ischemic strictures occur more than 0.5 cm proximal to the anastomosis and often
involve the hilum and multiple separate obstructions at the level of the sectoral or segmental
branch ducts. This can lead to a cholangiographic appearance that resembles primary scleros‐
ing cholangitis. NAS tend to occur earlier than AS, with a mean time to stricture development
of 3 to 6 months [55, 59].
Figure 5. Example of anastomotic stricture after cadaveric liver transplantation. A 57 year old man affected by alco‐
holic cirrhosis underwent a liver transplant nine months before presenting with elevation of the serum total bilirubin
and alkaline phosphatase. An abdominal Doppler ultrasound revealed normal portal vein, hepatic veins and hepatic
artery flow with mild dilatation of the intra-hepatic bile ducts. An endoscopic retrograde cholangiography (ERCP) was
ordered to assess the biliary tree and revealed the presence of a critical anastomotic stricture (Figure 5A, white arrow).
An inflatable endoscopic balloon measuring 10 mm in diameter and 4 cm in length was used to dilate the anastomot‐
ic stricture for 5 minutes (Figure 5B, white triangle). After dilating the anastomotic stricture, an occlusive cholangio‐
gram revealed an almost complete resolution of the anastomotic stenosis (Figure 5C, white arrow).
NAS are generally more difficult to treat than AS and can present with multiple episodes of
cholangitis requiring hospitalizations. Endoscopic therapy of NAS typically consists of 4- to
6-mm balloon dilation (compared with 6 to 8 mm for AS) followed by sphincterotomy, and
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placement of a 10.0- to 11.5-Fr plastic stent with replacement every 3 months [54]. The more
aggressive approach with the placement of a progressively increasing number of as well as
diameter stents with each subsequent ERC has been shown to be a successful method [93].
However, time to response with NAS is more prolonged than with AS and patients with NAS,
in average, require twice the number of interventions as patients with AS. The median time to
resolution of the stricture is 4-6 months for NAS versus 2 months for AS [59].
Outcomes of patients with NAS are not as favorable as for patients who develop AS. The 5-
year graft survival rate is 73% in patients with NAS, which is significantly lower than in
matched controls without strictures [89]. Only 50% to 75% of patients have a long-term
response with endoscopic therapy with dilation and stent placement [54, 59, 89, 73, 98].
Furthermore, up to 30% to 50% of patients will require re-transplantation or will die as a
consequence of this complication despite endoscopic therapy [54, 55, 63]. As a general rule,
ischemic events that lead to diffuse intrahepatic bile duct strictures are associated with poor
graft survival and will require retransplantation for suitable candidates.
Surgical revision may ultimately be required in patients with strictures that are refractory to
endoscopic or percutaneous treatment. A Roux-en-Y choledochojejunostomy is usually
performed in patients with duct-to-duct anastomosis. In those who already have a Roux-en-
Y anastomosis, a revision may be required by repositioning the bile duct of the graft to a more
proximal vascularized area.
15.2.4. Biliary stones, sludge and casts
Biliary filling defects are identified in approximately 5% of patients undergoing radiological
investigations after LT [99]. The vast majority of filling defects are caused by stones (70%)
followed by sludge, debris, blood clots, casts or migration of biliary stents [54, 89]. Biliary
anastomotic stenosis and intrahepatic strictures are the most frequent predisposing conditions
since they cause cholestasis and bacterial overgrowth that are well known risk factors for the
formation of sludge and biliary stones. Biliary duct stenoses are often caused by preservation
injury or by hepatic artery insufficiency. These are the two most common causes of ischemic
damage to the biliary tree that is highly dependent on the arterial blood supply for its metabolic
needs. When the biliary endothelium does not receive enough arterial blood flow, it sloughs
in the lumen of the biliary tree creating an optimal enviroment for the formation of crystals
and early calcification of the proteinaceous debris [99].
The management of filling defects in the biliary tree of patients undergoing LT is similar to the
non-transplant population and include sphincterotomy or dilatation of the sphincter of Oddi
and their extraction with the use of Dormia baskets or biliary balloons with the caveat that in
the presence of immunosuppressive agents, patients can have a rapid clinical decline in the
presence of undrained infected biliary ducts.
Because of the denervation of the liver graft and the use of steroids and other immunosup‐
pressive medications, LT patients affected by choledocholithiasis can be completely asymp‐
tomatic and afebrile even in the presence of bactobilia. LT patients affected by unrecognized
biliary occlusion can be completely asymptomatic for a long period of time and present with
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recurrent elevation of cholestatic serum markers that can mimick rejection, fevers of unknown
etiology, pancreatitis or cholangitis leading to sepsis and multiorgan failure in a very rapid
interval.
15.2.5. Stones
Stones usually form in the biliary tree of LT grafts proximally to a stricture or anastomotic
stenosis. Cyclosporine is known to promote supersaturation of bile and may contribute to the
formation of biliary stones in this group of patients. In one series, biliary stones were diagnosed
after a median of 19 months post LT and following their successful extraction, 17% reoccurred
within a median period of only 6 months [73]. In most cases (59% to 66%), a single ERCP session
with biliary sphincterotomy and balloon or basket extraction was sufficient to clear the bile
duct when the stones were located in the extra-hepatic system [73], while 2 or more sessions
were needed in 24% of patients and 3 or more sessions may be required in 17% of patients [73].
Advanced ERC techniques, such as intraductal lithotripsy or direct choledochoscopy should
be considered for all patients with large stones or for those stones located in a more proximal
biliary tract [84].
15.2.6. Casts
Biliary cast are defined as the presence of hardened, often dark and calcified protenaceous
material within the biliary system that takes the physical shape of the bile ducts. Biliary casts
are reported in 2.5% up to 18% of LT recipients [84, 99, 100]. Acute cellular rejection, ischemia,
infection, and biliary obstruction are well known risk factors for the development of casts after
LT.Most commonly they develop in the setting of ischemia, for example after the development
of hepatic artery thrombosis and when there is stricturing of the biliary tree at the hilum [64].
The formation of biliary casts is associated with increased morbidity, mortality, and incidence
of rejection [84]. Typically it occurs within the first year after transplantation. Analysis of the
casts has shown that bilirubin is the primary element along with collagen, bile acid, and
cholesterol [101, 102, 103]. The true pathogenesis of biliary cast syndrome is unknown but it
is believed that ischemic factors and biliary strictures play an important role in its develop‐
ment. Another risk factor is an increase in warm ischemia time [103]. Several endoscopic
approaches have been described with variable success and often multiple procedures are
required. Unfortunately it has been reported that up to 22% of patients with biliary cast
syndrome will require retransplantation. Complete clearance of casts can be done in 60% of
patients by ERCP or when necessary by PTC [64]. Various combinations of sphincterotomy,
balloon and basket extraction, stent placement, and lithotripsy are often necessary in all those
situations where casts are difficult to extract or are located in multiple branches of the biliary
tree. Surgery is necessary only when endoscopic or percutaneous methods fail.
15.2.7. Sphincter of Oddi dysfunction
The sphincter of Oddi is a muscular structure that encompasses the confluence of the distal
common bile and the pancreatic duct as they penetrate the wall of the duodenum. The term
sphincter of Oddi dysfunction (SOD) has been used to describe a clinical syndrome of biliary
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or pancreatic obstruction related to mechanical or functional abnormalities of the sphincter of
Oddi. The true incidence of SOD after LT is not known but appears to a relatively rare
condition. It is postulated that in the posttransplant setting, denervation of the common bile
duct in the ampullary region secondary to surgical intervention may lead to the development
of a hypertonic sphincter causing SOD. The prevalence of SOD has been reported to be between
2% to 7% [50, 98] and should be suspected in patients with cholestasis and with a uniformly
dilated bile duct without filling defects. In LT recipients affected by SOD, abdominal pain may
not be present and can cause post-operative pancreatitis. SOD should be ruled out when other
causes of pancreatitis have not been found. The treatment of post LT patients affected by SOD
is endoscopic sphincterotomy that allows the release of the muscles of the sphincter with
reduction of the intra-luminal biliary and pancreatic hypertension. As for SOD in the non-
transplant setting, the risk of pancreatitis after an ERC is high and so temporary prophylactic
pancreatic stents after sphincterotomy should be placed if possible to avoid this risk.
16. Biliary complications after living donation and cardiac arrest
Biliary complications after LT from living donors and grafts from donors after cardiac death
are more frequent than in patients who receive full size grafts from brain dead donors. These
two groups of recipients represent an increasing number of patients as the available grafts
from brain dead donors have failed to match the needs of patients waiting for LT and need
some considerations.
Living donor grafts are obtained by removing the right or left hepatic lobes from healthy
donors. The advantages of using living donor grafts are the fact that the quality of the grafts
is usually excellent, that surgery can be performed electively when the recipient is in optimal
medical conditions and that the cold and warm ischemia times are minimized. On the other
hand, living donor LT is technically challenging as the liver graft is only a portion of the entire
liver and therefore there is an increased risk of perioperative hepatic insufficiency. The
increased risk of hepatic artery thrombosis is due to the fact that the lumen of the proper hepatic
artery is significantly smaller than the common hepatic artery and more prone to develop
intraluminal clots. In addition, there is an increased risk for bile leaking out from the inter‐
rupted intrahepatic ducts during the dissection of the liver parenchyma and, biliary leaks at
the level of the anastomoses between the right or left biliary ducts and the recipient’s native
common bile duct or the Roux-en-Y loop. These anastomoses are often characterized by their
small caliber and the fact that, often, there are several ducts that need to be put together.
The use of donors after cardiac arrest in LT has become an acceptable strategy to increase the
number of available grafts. The early experience with these grafts was considered acceptable
and several programs have embraced this practice. However, recent studies have reported that
the short and long term outcomes are inferior to grafts from donors who suffered brain death.
Among the most common causes of perioperative complications in this group are: biliary
necrosis, anastomotic and non-anastomotic strictures, anastomotic leaks and non-primary
graft function. These adverse events seem to be consequences of the warm ischemic insult
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occurring in hemodinamically unstable patients prior and during the obervation period
leading to cardiac arrest.
16.1. Recipients of living-donor liver grafts
Living-donor liver transplantation (LDLT) has been associated with a higher rate of bile leaks
than in comparision to deceased-donor LT: 31.8% versus 10.2%, respectively [104]. Factors
associated with increased biliary leaks are:the presence of 3 or more bile ducts, presence of
hepatitis C, the experience of the transplant center at performing LDLT,long duration of
surgery, donor age older than 50, and recipients with MELD greater than 35 [105, 45]. The most
likely reason for these complications include a relatively smaller duct size, hence a more
technically difficult anastomosis, and a higher chance of ischemic injury to the allograft [106].
Overall, biliary complications occur more frequently in recipients receiving a right graft than
a left liver graft. In right liver graft recipients with single biliary reconstruction, duct-to-duct
anastomosis involving a small-sized duct (<4 mm in diameter) is more of a risk for biliary
complications than when a hepatico-jejunostomy is used with these duct sizes [107]. A
decreased incidence of biliary complications with a Roux-en-Y reconstruction has been found
in some [104], but not all, studies [108]. Endoscopic management in LDLT recipients may be
quite difficult because of the complex nature of the duct-to-duct reconstruction. Patients will
often require frequent endoscopic retrograde cholangiographies (ERCs) with the use of smaller
caliber stents (7.0–8.5 Fr). ERC with balloon dilatation is successful in up to 65% of patients.
Failure of a primary ERC with dilatation is associated with the appearance of late biliary
strictures over 24 weeks from LT and more than 8 weeks between a twofold increase in serum
alkaline phosphatase [109]. The relapse rate of strictures is up to 30% and occurs more in
patients with shorter duration of stenting. In addition to the recipient, donors also experience
biliary complications and should be made aware of this before undergoing donation. In a
multicenter study that evaluated the outcome of 393 donors, bile leaks occurred in 36 patients
(9%) and most of these patients required a prolonged intensive care unit stay [110]. Biliary
complications in donors are seen more often with right lobe donation and the management is
the same as described for the recipients.
16.2. Recipients of grafts from donation after cardiac death
The continuing shortage of organs has led to expansion of the donor pool and consideration
of non-heart beating liver donation or donation after cardiac death (DCD). DCD is associated
with significant risk for both early and late biliary complications. In a retrospective analysis
of 20 recipients of organs from DCD in the United States, 12 out of 20 patients (60%) developed
serious biliary complications [65]. Most recipients developed more than one biliary complica‐
tion including bile leaks requiring liver re-transplantation, anastomotic strictures, hilar
strictures, extra-hepatic donor duct stricture, stones, casts, and biliary debris. In 50% of the
patients, biliary strictures were proximal to the anastomosis. Unlike conventional liver
transplantation where non-anastomotic strictures (NAS)are usually attributed to ischemic
preservation injury or vascular compromise due to hepatic artery failure, NAS in DCD
recipients reflects ischemic injury that occurred before organ retrieval [65]. An analysis of 172
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Korean recipient survivors confirmed the increased rate of biliary complications in DCD-
related liver transplantation [111] and also illustrated the impact of the location of the stricture
and its relation to graft survival. Patients with unilateral or at the confluence biliary strictures
could be managed endoscopically with dilatation and stenting while diffuse or bilateral
strictures failed endoscopic interventions [111, 112, 113]. Unilateral and bilateral or diffuse
biliary strictures were associated with 86 and 0% long-term survival, respectively [111, 112,
113]. Intra-hepatic biliary strictures are also associated with increased incidence of biliary
sludge, cast formation, recurrent cholangitis, and biliary fibrosis [65].
17. Future directions
Use of new intraductal endoscopy technologies such as the SpyGlass® direct visualization sys‐
tem (Boston Scientific®, Natick, MA, USA), which allows visualization of the inner wall of the
biliary tree and can act as the guidance system for passage of the guide wire through a tight stric‐
ture, has shown some early promise in this area [84, 114, 115, 116]. New types of balloons and
stents will have significant role in improvement of management of biliary stricture. Preliminary
evidence shows that peripheral cutting balloons may be more effective for the treatment of be‐
nign biliary strictures not responsive to standard balloon dilatation [117]. Metal stents have been
employed in an effort to reduce stricture recurrence and maintain duct patency. Traditional
open-mesh metal stents are associated with occlusion, stone formation and epithelial hyperpla‐
sia that reduce their patency rate [118]. These disadvantages of metal stents have traditionally
limited their use for benign biliary strictures. The drawbacks of uncovered metal stents have led
to the development of covered metal stents, as they can be removed during ERCP after the reso‐
lution of the biliary complication. However, the use of covered metal stents for the management
of biliary complications in LT recipients needs further evaluation, as their safety and effective‐
ness have not been fully established. New technologies have introduced the possibility of em‐
ploying self-expanding stents made of bioabsorbable material that theoretically will offer
several advantages compared to the plastic and self-expanding metal stents [119, 120]. Studies in
porcine models have shown that these stents have better patency rates because of their larger di‐
ameter, lower biofilm accumulation and reduced incidence of bile duct proliferative changes
that often cause occlusion of metallic stents. Furthermore, patients do not have to undergo addi‐
tional procedures to remove the stents. Bioabsorbable stents can also be impregnated with phar‐
maceutical compounds, such as antimicrobial agents that make them an optimal choice for
patients who are affected by local biliary infections. However, these stents remains investiga‐
tional at the present time.
18. Summary
The overall landscape of the management of biliary complications after LT has changed rather
rapidly in the past 2 decades. In the past, the conventional management of these conditions
was mainly surgical. With the advancement of endoscopic equipments and accessories,
therapeutic endoscopy has been playing a major role in the treatment of post-liver transplant
biliary complications. Percutaneous and surgical modalities are now reserved only for patients
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in whom endoscopic treatment fails and for those with multiple inaccessible intrahepatic
strictures or Roux-en-Y anastomoses.
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